<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC6963560/results/search/test_trace/results.xml">
  <result pre="Glomerular disease is an extra-hepatic manifestation of hepatitis C virus" exact="infection" post="(HCV) and membranoproliferative glomerulonephritis is the most frequent glomerular"/>
  <result pre="selective or non-specific immunosuppressive drugs, immunomodulators, and symptomatic agents. The" exact="treatment" post="of HCV-associated glomerular disease is dependent on the clinical"/>
  <result pre="than 71 million people have chronic hepatitis C virus (HCV)" exact="infection" post="worldwide. HCV is a major health problem, and long"/>
  <result pre="an important antigenic stimulus for clonal B cell expansion. The" exact="detection" post="of circulating cryoglobulins is frequent in patients with chronic"/>
  <result pre="2–3% develop vasculitic symptoms that characterize HCV-mixed cryoglobulinemia syndrome. HCV" exact="infection" post="is the main cause of mixed cryoglobulinemia, a systemic"/>
  <result pre="affected by HCV genotype, viral load, or duration of HCV" exact="infection" post="[1,2]. Mixed cryoglobulinemia (MC) represents 60–75% of all cryoglobulinemia"/>
  <result pre="review is to report the most important data concerning the" exact="treatment" post="of HCV-related glomerular disease, an important extra-hepatic complication of"/>
  <result pre="damage at kidney level [5]. A role of chronic HCV" exact="infection" post="in the pathogenesis of CKD has been suggested by"/>
  <result pre="nature. Patients on maintenance dialysis remain at risk for HCV" exact="infection" post="due to nosocomial transmission of HCV and have a"/>
  <result pre="due to nosocomial transmission of HCV and have a high" exact="prevalence" post="of HCV infection. On the other hand, a significant"/>
  <result pre="infection. On the other hand, a significant frequency of HCV" exact="infection" post="has been noted in patients with renal insufficiency at"/>
  <result pre="CKD are remarkable public health problems worldwide. The overall mean" exact="prevalence" post="of CKD in the general population is around 13.4%"/>
  <result pre="hypertension, smoking, weight overload) do not explain completely the current" exact="prevalence" post="of chronic kidney disease in the adult general population"/>
  <result pre="therapy has been given with the idea that the underlying" exact="infection" post="promotes the synthesis of immune complexes and resultant glomerular"/>
  <result pre="RBV mono-therapy proved to be effective and safe in the" exact="treatment" post="of HCV-induced glomerular disease post liver transplant due to"/>
  <result pre="ARBs) drugs should be considered. Unlike HBV and HIV, HCV" exact="infection" post="can be completely and permanently treated by antiviral medications"/>
  <result pre="at baseline and repeated kidney biopsies 14–26 months after antiviral" exact="treatment" post="ended. They found lowered glomerular inflammation, and renal vasculitic"/>
  <result pre="of combined antiviral therapy (pegylated IFN plus RBV) for the" exact="treatment" post="of HCV-MCS in non-immunosuppressed population were also evaluated. 10"/>
  <result pre="replication. Three groups of DAAs are now available for the" exact="treatment" post="of HCV. These include NS3/4A protease inhibitors, NS5A inhibitors,"/>
  <result pre="protease inhibitors (telaprevir and boceprevir) have been introduced for the" exact="treatment" post="of HCV in combination with pegylated IFN and RBV"/>
  <result pre="(2011). The triple combined antiviral regimens (IFN/RBV/telaprevir or boceprevir) increased" exact="treatment" post="success, but were poorly tolerated [13]. The standard of"/>
  <result pre="[15]. The daily fixed-dose elbasvir/grazoprevir regimen is recommended for the" exact="treatment" post="of genotype 1 infection in patients with severe renal"/>
  <result pre="elbasvir/grazoprevir regimen is recommended for the treatment of genotype 1" exact="infection" post="in patients with severe renal dysfunction. The C-SURFER study"/>
  <result pre="elbasvir/grazoprevir combination is effective in patients with HCV genotype 1" exact="infection" post="and CKD stage 4/5 [16]. However, elbasvir/grazoprevir shows efficacy"/>
  <result pre="with HCV genotype 1, 2, 3, 4, 5, and 6" exact="infection" post="[17]. Finally, we suggest that serum creatinine and urinary"/>
  <result pre="should be monitored with accuracy in all patients after antiviral" exact="treatment" post="with DAAs. New–onset or relapsing glomerular disease has been"/>
  <result pre="near future with the introduction of DAAs provided with reduced" exact="treatment" post="duration and lower prices; this will be an additional"/>
  <result pre="until the acute phase of disease is overcome. After that," exact="treatment" post="with DAAs is suggested. The initial approach includes immunosuppressive"/>
  <result pre="DAA therapies should be given immunosuppressive agents. In all cases," exact="treatment" post="with antiproteinuric agents such as angiotensin-converting enzyme inhibitors and/or"/>
  <result pre="the patients (n = 11), including severe infections. Episodes of" exact="infection" post="had been observed mainly in a subgroup of patients"/>
  <result pre="kidney diseaseAm. J. Kidney Dis.20136162363710.1053/j.ajkd.2012.08.04023102733 2.RutledgeS.ChungT.SiseM.Treatment of hepatitis C virus" exact="infection" post="in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritisHemodial."/>
  <result pre="with impaired renal functionLiver Int.20163680781610.1111/liv.1310226923436 16.RothD.NelsonD.R.BruchfeldA.LiapakisA.SilvaM.MonsourH.Jr.MartinP.PolS.LondoñoM.C.HassaneinT.et al.Grazoprevir plus elbasvir in" exact="treatment" post="naïve and treatment-experienced patients with hepatitis C virus genotype"/>
  <result pre="naïve and treatment-experienced patients with hepatitis C virus genotype 1" exact="infection" post="and stage 4–5 chronic kidney disease (the C-SURFER study)Lancet20153861537154510.1016/S0140-6736(15)00349-926456905"/>
  <result pre="al.Lupus-like immune complex-mediated glomerulonephritis in patients with hepatitis C virus" exact="infection" post="treated with oral, interferon-free, direct-acting antiviral therapyKidney Int. Rep.2016113514310.1016/j.ekir.2016.06.00627990496"/>
  <result pre="therapyRheumatology2016552084208510.1093/rheumatology/kew26827338085 25.EmeryJ.S.KuczynskiM.LaD.AlmarzooqiS.KowgierM.ShahH.WongD.JanssenH.L.FeldJ.J.Efficacy and safety of direct acting antivirals for the" exact="treatment" post="of mixed cryoglobulinemiaAm. J. Gastroenterol.20171121298130810.1038/ajg.2017.4928291241 26.SaadounD.PolS.FerfarY.AlricL.HezodeC.AhmedS.N.S.de Saint MartinL.ComarmondC.BouyerA.S.MussetL.et al.Efficacy"/>
  <result pre="Saint MartinL.ComarmondC.BouyerA.S.MussetL.et al.Efficacy and safety of sofosbuvir plus daclatasvir for" exact="treatment" post="of HCV-associated cryoglobulinemia vasculitisGastroenterology2017153495210.1053/j.gastro.2017.03.00628288791 27.BonacciM.LensS.MariñoZ.LondoñoM.C.Rodriguez-TajesS.Sánchez-TapiasJ.M.Ramos-CasalsM.Hernández-RodríguezJ.FornsX.Long-term outcomes of patients with"/>
  <result pre="with HCV-associated cryoglobulinemic vasculitis after virologic cureGastroenterology201815531131510.1053/j.gastro.2018.04.02429705529 28.FabriziF.AghemoA.LamperticoP.FraquelliM.CresseriD.MoroniG.PasseriniP.DonatoF.M.MessaP.Immunosuppressive and antiviral" exact="treatment" post="of hepatitis C virus-associated glomerular disease: A long-term follow-upInt."/>
  <result pre="J. Artif. Organs20184130631810.1177/039139881876235829595085 29.ObriscaB.JuribitaR.SorohanB.IliescuL.BastonC.BobeicăR.AndronesiA.LecaN.IsmailG.Clinical outcomes of HCV-associated cryoglobulinemic glomerulonephritis following" exact="treatment" post="with direct acting antiviral agents: A case-based reviewClin. Rheumatol.201910.1007/s10067-019-04625-y"/>
  <result pre="A case reportClin. Exp. Hepatol.2018410010329904727 32.ElmowafyA.Y.El MaghrabiH.M.ZahabM.A.ElwasifS.M.BakrM.A.Sofosbuvir and daclatasvir in" exact="treatment" post="of HCV-related membranoproliferative glomerulonephritis with cryoglobulinemia in a patient"/>
  <result pre="associated membranoproliferative glomerulonepritis treated with direct-acting antiviralsIndian J. Nephrol.20182846246430647501 34.ChiaX.X.CherepanoffS.DantaM.FurlongT.Successful" exact="treatment" post="of HCV-related glomerulonephritis with sofosbuvir and daclatasvirNephrology2018333738010.1111/nep.1308729520905 35.De VitaS.QuartuccioL.IsolaM.MazzaroC.ScainiP.LenziM.CampaniniM.NaclerioC.TavoniA.PietrograndeM.et"/>
  <result pre="35.De VitaS.QuartuccioL.IsolaM.MazzaroC.ScainiP.LenziM.CampaniniM.NaclerioC.TavoniA.PietrograndeM.et al.A randomized controlled trial of rituximab for the" exact="treatment" post="of severe cryoglobulinemic vasculitisArthritis Rheum.20126484385310.1002/art.3433122147661 36.SnellerM.HuZ.LangfordC.A randomized controlled trial"/>
  <result pre="Reports on two casesWorld J. Clin. Cases2015373674210.12998/wjcc.v3.i8.73626301235 41.FabriziF.MartinP.ElliA.MontagninoG.BanfiG.PasseriniP.CampiseM.R.TarantinoA.PonticelliC.Hepatitis C virus" exact="infection" post="and rituximab therapy after renal transplantationInt. J. Artif. Organs20073044544910.1177/03913988070300051317551909"/>
  <result pre="pathogens-08-00176-t002_Table 2Table 2 Regimens based on DAAs currently available for" exact="treatment" post="of HCV in CKD. Daclatasvir (60 mg) CKD stage"/>
 </snippets>
</snippetsTree>
